

# UCSF

## UC San Francisco Previously Published Works

### Title

Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RAR $\alpha$  Dependency Targetable by SY-1425, a Potent and Selective RAR $\alpha$  Agonist.

### Permalink

<https://escholarship.org/uc/item/50t8p08t>

### Journal

Cancer Discovery, 7(10)

### Authors

McKeown, Michael

Corces, M

Eaton, Matthew

et al.

### Publication Date

2017-10-01

### DOI

10.1158/2159-8290.CD-17-0399

Peer reviewed



Published in final edited form as:

*Cancer Discov.* 2017 October ; 7(10): 1136–1153. doi:10.1158/2159-8290.CD-17-0399.

## Super-Enhancer analysis defines novel epigenomic subtypes of non-APL AML including an RAR $\alpha$ dependency targetable by SY-1425, a potent and selective RAR $\alpha$ agonist

Michael R McKeown<sup>1,\*</sup>, M. Ryan Corces<sup>3,\*</sup>, Matthew L Eaton<sup>1,\*</sup>, Chris Fiore<sup>1,\*</sup>, Emily Lee<sup>1</sup>, Jeremy T Lopez<sup>1</sup>, Mei Wei Chen<sup>1</sup>, Darren Smith<sup>1</sup>, Steven M. Chan<sup>4,3</sup>, Julie L. Koenig<sup>3</sup>, Kathryn Austgen<sup>1</sup>, Matthew G Guenther<sup>1</sup>, David A. Orlando<sup>1</sup>, Jakob Lovén<sup>1</sup>, Christian C Fritz<sup>1</sup>, and Ravindra Majeti<sup>2,3</sup>

<sup>1</sup>Syros Pharmaceuticals, 620 Memorial Drive, Cambridge, MA 02139

<sup>2</sup>Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305

<sup>3</sup>Program in Cancer Biology, Cancer Institute, Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center Stanford University School of Medicine, Stanford, CA 94305, USA

<sup>4</sup>Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

### Abstract

We characterized the enhancer landscape of 66 AML patients, identifying 6 novel subgroups and their associated regulatory loci. These subgroups are defined by their super-enhancer (SE) maps, orthogonal to somatic mutations, and are associated with distinct leukemic cell states. Examination of transcriptional drivers for these epigenomic subtypes uncovers a subset of patients with a particularly strong super-enhancer at the retinoic acid receptor alpha (*RARA*) gene locus. Presence of a *RARA* SE and concomitant high levels of *RARA* mRNA predisposes cell lines and ex vivo models to exquisite sensitivity to a selective agonist of RAR $\alpha$ , SY-1425 (tamibarotene).

Furthermore, only AML patient-derived xenograft (PDX) models with high *RARA* mRNA were found to respond to SY-1425. Mechanistically, we show that the response to SY-1425 in *RARA*-high AML cells is similar to that of APL treated with retinoids, characterized by the induction of known retinoic acid response genes, increased differentiation, and loss of proliferation.

### Keywords

AML; Enhancer; RAR $\alpha$ ; SY-1425; MDS

---

Corresponding Authors: Christian Fritz, PhD, Syros Pharmaceuticals, 620 Memorial Drive, Cambridge, MA 02139, cfritz@syros.com, Phone: (617) 674-9063, Fax: (617) 744-1377. Ravindra Majeti MD, PhD, Stanford University School of Medicine, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Lokey Stem Cell Building, 265 Campus Drive, Stanford, CA 94305-5463, rmajeti@stanford.edu, Phone: 650-721-6376, Fax: 650-736-2961.

\*These authors contributed equally

### Disclosure of Potential Conflicts of Interest

MRM, MLE, CF, EL, JTL, MGG, MWC, DS, DO, JTL, KA, and CCF are shareholders of Syros Pharmaceuticals. MRC, SMC, JLK and RM have no conflicts of interest to report.

## INTRODUCTION

AML is the most common acute leukemia in adults (1) with an estimated 4 new cases diagnosed per 100,000 individuals in the United States in 2015 (SEER data, 2016(2)). Current treatment involves chemotherapy-based induction and consolidation with potential curative use of hematopoietic cell transplantation (HCT) in those eligible patients who respond to treatment. New therapeutic options are needed for AML patients given a 5-year overall survival of only 35–40%. Myelodysplastic syndrome (MDS) is a heterogeneous hematopoietic disease commonly associated with bone marrow failure. While early MDS is considered an indolent disease, the prognosis of patients with later stage MDS is poor and is associated with a low overall survival similar to AML. We sought to characterize the epigenomic circuitry and transcriptional state of leukemic cells to identify potential new treatments beyond those discovered by mutational analysis of protein coding genes.

To date, a large part of cancer research has focused on somatic mutations in protein coding regions to identify putative oncogenic drivers (3). Recently, large, highly active chromatin regions, named “super-enhancers” (SEs) have been described that define cell identity and cell state in normal and malignant cells, including cancer cells (4–6). While typical enhancers are short (~1 kb) stretches of DNA that regulate the expression of genes through the binding of transcription factors (TFs) and subsequent recruitment of RNA Pol II and associated proteins, SEs are larger in size (>20 kb on average) and are characterized by a much higher occupancy of transcriptional regulatory proteins (5,6). Previous work has shown that the histone three lysine-27 acetylation (H3K27ac) mark can be used as an efficient and robust means of super-enhancer demarcation (6–13). It has been shown that within a given cell, these few, highly active chromatin regions (<5% of all enhancers) tend to regulate key genes governing cell identity and phenotype. In tumor cells, this includes oncogene and non-oncogene drivers of the transformed state (7,8).

To define contributions of the non-coding genome in AML, we characterized the enhancer, super-enhancer, gene expression, and mutational landscapes of blasts from 66 AML patients and used this information to dissect transcriptional regulatory circuitry and predict therapeutic targets. De novo stratification of these enhancer profiles identified six distinct patient subgroups, independent of and orthogonal to mutational status. From this, we demonstrate that retinoic acid receptor alpha (RAR $\alpha$ ) occupies a critical node in the transcriptional network of a new subgroup of AML, putatively identifying a novel tumor cell liability that could be exploited therapeutically.

The selective and potent RAR $\alpha$  agonist SY-1425 (tamibarotene) has been demonstrated to possess improved pharmacologic properties over first generation pan-retinoids such as all-trans retinoic acid (ATRA) (14–18). We found that SY-1425 potently and selectively inhibits the proliferation of AML cell lines that contain a strong SE at the *RARA* locus. This observation was confirmed in AML patient derived xenograft (PDX) models whereby RARA-high AML models are more sensitive to SY-1425 treatment than RARA-low AML models. We also observe *RARA* SEs and overexpression of *RARA* mRNA in MDS. These data provide the foundational support for investigating SY-1425 as a treatment option for AML and MDS patients with a strong *RARA* super-enhancer.

## RESULTS

### Identification and mapping of super-enhancers in AML

Using a high-throughput H3K27ac chromatin immunoprecipitation platform (Fig. 1A), we profiled the landscape of active enhancers in blasts from 66 AML donors, 28 AML cell lines, 4 FACS-purified HSPC samples, and 6 FACS-purified monocyte samples (Supplementary Fig. S1A). Four patient samples were excluded from the analysis due to low ChIP-seq quality. Using methods described previously (19), we identified individual enhancer loci and super-enhancers, revealing a median of 807 SEs per sample with a median length of 22 kb (Fig. 1B and Supplementary Fig. S1B–C) with enhancer ‘score’ reflecting both enhancer size and density of reads (see supplemental methods). As identified in previous studies, SEs are large, highly active regions of chromatin that regulate a small subset of genes critical to cell identity and state (4–6). This approach provided robust enhancer profiles with high technical replicate consistency (Supplementary Fig. S1D) and enabled the identification of a sample purity threshold (% AML blast cells) of 80% as a requirement for patient inclusion in this study (Supplementary Fig. S1E–G).

To link SEs to genes, we utilized the correlation between SE score and H3K27ac abundance at promoters of genes within 500 kb of the enhancer, predicting a link when the p-value of the correlation was significant genome-wide, or when an SE lacked any significant correlation, linking it to the best correlated and nominally significant gene (Supplementary Fig. S2A–D; see supplementary methods). Most SEs are linked to multiple genes with this approach yielding on average 2.7 links per SE (Supplementary Fig. S2E). We then compared the SE to gene linking from this correlation method in primary AML patients to published chromatin conformation data from promoter capture Hi-C (PChi-C) in monocytes (20) and found that 62% of SEs had validated linking.

### Super-enhancer analysis reveals cell differentiation state and 6 distinct AML clusters

Previous work has identified the differentiation state of AML cells as a primary source of epigenetic variation (21–23). This is consistent with the observation that certain key HSPC enhancers, such as the SE linked to CDK6, show strong variability across our AML cohort (Fig. 1C). In an effort to assess how well SE maps can distinguish differentiation states in primary AML samples, we defined the extremes of myeloid differentiation by constructing SE maps from HSPCs and monocytes. We defined signatures of differentiation state based on the top 20 HSPC- and monocyte-specific SEs (Fig. 1D). Assessment of this enhancer-based HSPC signature within the 62 primary AML blasts shows a robust inverse correlation between HSPC-specific enhancers and monocyte-specific enhancers (Supplementary Fig. S3A). To quantify AML blast utilization of an HSPC-like enhancer signature, we derived a predicted HSPC score (Fig. 1D, green bar). This score defines the stem-like (high HSPC score) or differentiated (low HSPC score) state of a given AML sample. To determine if this differentiation state is linked to one of the major genome-wide enhancer programs, we employed independent components analysis (ICA) to find the two most pervasive enhancer signatures in the genome (Fig. 1E). The first IC, termed Myeloid Differentiation, accounted for, on average, 21.4% of the variance of SEs genome-wide, and correlated strongly with the predicted HSPC score ( $R^2=0.85$  Supplementary Fig. S3B). The second IC, termed HOX

Factor Activation, accounted for an average of 11.5% of the variance, and correlated with enhancers associated with homeobox (HOX) genes, *PBX3*, and *MEIS1*, among others (Supplementary Fig. S3C). These TFs have been shown to co-occupy enhancers in murine models of leukemia, acting in concert to drive leukemogenesis and enforce immature differentiation states (24,25). Together, these two independent components accounted for 33% of the variance in the data, providing motivation for a higher-dimensional analysis.

To this end, we performed non-negative matrix factorization consensus clustering (NMF-C) (see supplemental methods) amongst the patient samples to group the patients by enhancer score. This approach identified 6 distinct subgroups of patients (referred to as clusters) in our AML cohort (Fig. 1F), each characterized by a unique combination of enhancer profiles (Supplementary Fig. S3D–E). While not included in the factorization, the HSPC and monocyte H3K27ac profiles were inserted into the clustering to illustrate their respective enhancer profiles (Fig. 1F, light blue and purple respectively). This demonstrates that cluster 2 was characterized by enhancers also found in monocytes, while cluster 5 utilized enhancers active in HSPCs. Additionally, the 6 clusters showed robust internal association by Pearson correlation of enhancer activity (Supplementary Fig. S3F). Despite clear separation in NMF-C, some clusters also showed strong inter-cluster correlation, with two groups of clusters: 1 and 2 and 3–6, showing high inter-cluster similarity (Supplementary Fig. S3F). This similarity is driven by the HSPC signature score of the samples within the clusters, with clusters 1 and 2 being far more monocyte-like than clusters 3–6 (Fig 1G, Supplementary Fig. S3G).

### Characterization of distinct super-enhancer-based subgroups of AML

Using the clusters defined by overall SE distribution, we then focused on identifying the specific SE-linked genes forming the basis of these clusters. Prominent among these were SEs associated with known AML master TF genes (ex. *HOXA/HOXB/MEIS1*), an HSPC specific gene (*PROM1*), and a monocyte specific factor gene (*IRF8*) (Fig. 2A). These core transcription factors suggest that the clusters arise from shared underlying master regulatory circuitry.

To assess the interplay between somatic mutations in protein coding genes and our SE-based clustering, we performed targeted genotyping on all samples to identify mutations in known leukemia-associated genes (Fig. 2B, Supplementary Table S1). The 130 genes sequenced included any gene found by whole exome sequencing to be mutated in more than 2% of AML cases (26) (Supplementary Table S1). These patient samples were also profiled for the presence of common prognostic cytogenetic abnormalities as part of routine clinical pathology tests. Comparing targeted genotyping and cytogenetics with our clustering, we observe that all patients with known MLL translocation are sorted into cluster 1 by their global enhancer profiles (Fig 2B,  $p < 1.6E-7$ ). However, we note that 12 of our patients have not been genotyped for MLL translocation. Nevertheless, this suggests that MLL translocations may induce a unique epigenetic state that dominates the overall enhancer landscape of the given AML sample, not surprising given the function of MLL fusion proteins in mis-regulating DOT1L function leading to aberrant histone H3K79 methylation

(27). While mutations in *NPM1* and *FLT3* are enriched in clusters 2, 3, 4, and 6, no cluster-specific associations were observed for mutations in *DNMT3A*, *TET2*, and *IDH1* and *IDH2*.

To better understand the cluster-specific SEs driving our patient grouping, we visualized the median per-cluster SE score for the most influential SEs in the NMF decomposition (Fig. 2C). Clear cluster-specific SEs were dominated by genes with known roles in AML such as *MEIS1*, *PROM1*, *SOCS2*, and *ERG* among others (28,29). A pattern of cluster-specific SE usage emerged, with each cluster being regulated by a relatively compact number of individual super-enhancers.

### Super-enhancer-defined patient clusters show differences in overall survival

To understand whether clustering of AML patient samples by enhancer landscape is biologically meaningful, we asked whether SE-defined clusters could be associated with other biological differences by bridging to a large patient data set (26). Our patient sample cohort showed a bias towards high blast count and *FLT3*-ITD positivity compared to other surveys of AML (30) (Supplementary Fig. S4A) and shows a median patient survival of 13.1 months from diagnosis (Supplementary Fig. S4B). However, the relatively small numbers of patients in the SE based clustering make robust correlations with clinical factors difficult. As an exploratory investigation, we attempted to bridge to well annotated expression based databases since ours was already the largest SE database in AML available. Thus, we developed a 1,710 gene transcriptional signature as a proxy for our SE profiling clusters and projected this scheme into the patients profiled by The Cancer Genome Atlas Consortium (Supplementary Fig. S4C–D, Supplementary Table S2, see methods). By expression, the TCGA clusters 1 and 2, which already showed some overlapping SEs, were combined in the classification as their transcriptional signatures were too similar to reliably distinguish their members on cross validation. While this analysis is not meant to replace established clinical AML prognostic categories or patient stratification, we note that enhancer clusters were associated with significantly different survival outcomes in univariate analysis ( $p < 0.013$ , Supplementary Fig. S4E, Supplementary Table S3) which could not be accounted for by somatic mutation differences (Supplementary Fig. S4F). This suggests that enhancer profiles may provide orthogonal information to mutations in the coding region of the genome motivating future studies into the clinical relevance of enhancer landscapes.

### An SE drives the *RARA* gene in a subset of AML

To identify targets for putative therapeutic intervention, we inferred a mutual information network of coordinated SEs across the clusters, and hypothesized that TFs in this network are key drivers of the transcriptional circuitry in these patients (Fig. 3A). Some TFs showed concomitant enrichment of their DNA binding motif in cluster-specific enhancers setting the foundation for the cell's nuclear circuitry (Fig. 3A, red outline). One enhancer that was highly differential between patient samples is associated with the retinoic acid receptor  $\alpha$  (*RARA*) gene (Fig. 3B–C, Supplementary Fig. S5A). In some cases, this enhancer was one of the strongest present genome-wide (Fig. 3D) and the most correlated enhancer with the *RARA* gene by expression. Overall, the *RARA* enhancer ranked among the top 100 enhancers in 25% of samples (Fig. 3E). For 59% of the samples, the *RARA* enhancer was classified as an SE, suggesting that the AML blasts from these individuals have committed a

significant amount of transcriptional machinery to this locus. Indeed, *RARA* expression was significantly higher in the top 25% of samples in which the *RARA* enhancer ranked in the top 100 enhancers and was correlated with enhancer score overall (Fig 3F, Supplementary Fig. S5B). While translocations involving the *RARA* gene are common in acute promyelocytic leukemia (APL) (31), only two of the patients in our cohort harbored *RARA* fusions, and enhancer based clustering did not place these samples into cluster 2 where *RARA* SE samples were enriched (Fig. 3B, Supplementary Fig. S5A). The *RARA* SE itself is located over the gene body of *RARA* in AML, MDS, and normal monocytes (Fig. S5A&C) with acetylation spanning the active promoter and several introns and exons. Moreover, the size of the enhancer correlates with the expression of *RARA* in our patient samples further supporting a direct link of this overlapping enhancer and gene. Importantly, published PCHi-C data (20) validate the three-dimensional interaction of the *RARA* promoter with the *RARA* SE (Supplementary Fig. S5C).

Given the similarities between AML and MDS, we also investigated the *RARA* locus in MDS and normal bone marrow CD34+ HSPCs. Analysis of a public data set (32) comparing gene expression in MDS CD34+ cells with normal CD34+ cells revealed that a subset of MDS cells have elevated *RARA* mRNA levels, similar to that seen in our AML dataset (Supplementary Fig. S5D). By analyzing bone marrow aspirates from two MDS patients, we detected *RARA* SEs with comparable score to those in AML (Supplementary Fig. S5E). In contrast, in normal bone marrow CD34+ cells, the *RARA* locus was not associated with an SE and H3K27ac levels were similar to AML blasts that do not contain a SE at this locus.

Overall, the fact that the *RARA* SE is one of the largest SEs detected in a subset of patient samples raises the hypothesis that these cells may be dependent on the function of overexpressed RAR $\alpha$ .

### **An *RARA* SE predicts sensitivity *in vitro* to an RAR $\alpha$ agonist in non-APL AML**

We asked whether the presence of a strong SE for *RARA* in non-APL AML cells could be predictive for sensitivity of such cells to RAR $\alpha$  targeted compounds and identified a series of models to test this (Supplementary Fig. S5F). As in primary patient samples, the score of the *RARA* enhancer and the corresponding mRNA expression varied across a collection of non-APL AML cell lines (Fig. 4A, Supplementary Table S4). Four cell lines with strong enhancers (MV4-11, OCI-AML3, Sig-M5, and EOL1) and two with weak enhancers (HEL, and KG1a), hereafter referred to as RARA-high and -low, were used as initial models for differences in *RARA* SE score observed in our primary patient samples. RAR $\alpha$  targeted agents were chosen for both selective agonism and antagonism. We first identified a potent and selective RAR $\alpha$  agonist from the literature, tamibarotene (referred to as SY-1425 in the rest of the manuscript), which has previously been well validated as a selective and potent RAR $\alpha$  agonist (14,16,17), and was further confirmed by us in biochemical and cellular assays (Supplementary Fig S6A-B).

RARA-high and low cell lines were treated with a range of concentrations of SY-1425 and assessed for proliferation (Fig. 4B). While SY-1425 was a potent inhibitor of proliferation in the RARA-high AML cell lines, with EC50s that ranged from 0.14 nM-0.9 nM, there was no effect on the RARA-low cell lines up to the highest concentration tested (2  $\mu$ M). A broader



panel of non-APL AML cell lines further confirmed the positive correlation of both *RARA* mRNA (11 cell lines, Supplementary Fig. S7A) and enhancer score (13 cell lines, Supplementary Fig. S7B) with SY-1425 sensitivity, with responders showing significantly higher *RARA* enhancer score (one-sided t-test,  $p=0.03$ ), and a correlation of enhancer score and mRNA levels (Supplementary Fig S7C). To confirm that the effect of SY-1425 was indeed mediated by agonism of *RAR $\alpha$* , we tested the effect of a *RAR $\alpha$*  selective antagonist, BMS195614 (18), alone or in combination with SY-1425 on AML cells. The antagonist did not show any anti-proliferative effect on *RARA*-high or *RARA*-low cell lines by itself (Supplementary Fig. S7D). Furthermore, co-administration of high concentrations of the antagonist with SY-1425 was found to completely rescue the effect of SY-1425 in the *RARA*-high cell line SigM5. Co-treatment with the *RAR $\alpha$*  antagonist had no effect on growth inhibition by idarubicin, a DNA intercalator (Supplementary Fig. S7E). These results support the hypothesis that SY-1425 exerts its anti-proliferative effects on AML cells specifically through activation of *RAR $\alpha$* .

### ***RARA* mRNA levels correlate with SY-1425 sensitivity *in vivo***

To further strengthen our hypothesis that an SE at the *RARA* locus induces high levels of *RARA* transcripts, resulting in a cell state that is sensitive to a selective *RAR $\alpha$*  agonist, we tested the effects of SY-1425 on four patient derived mouse xenograft models (PDXs) of AML. The four PDX models are disseminated AML leukemia models where treatment is initiated when a 2–7% AML blast burden is detected in the peripheral blood of inoculated mice. This usually occurs about 20–40 days after inoculation with human tumor cells depending on the model. Mice were treated daily with 6 mg/kg SY-1425 orally, a dose that was chosen to match the human exposure when APL patients are treated clinically with tamibarotene, and similarly studied for the non-selective retinoid ATRA (Supplementary Fig. S8A–B) (33,34). We used two PDX models (AM5512 and AM8096) where the tumor cells contained high levels of *RARA* mRNA and compared the effects of SY-1425 to two models where the tumor cells contained low levels of *RARA* mRNA (AM7577 and AM7440) (Supplementary Fig. S9A). We observed significant reductions of AML blasts (measured using anti-human CD45 antibody) in peripheral blood in the two *RARA*-high models (Fig. 4C–D) but no effect of SY-1425 in the two *RARA*-low models (Fig. 4E–F). The reduction in circulating tumor cells in the *RARA*-high models was also associated with blast reduction in bone marrow and spleen (Supplementary Fig. S9B–C) and led to significant prolongation of survival compared to vehicle in these aggressive models of human AML (Supplementary Fig. S9D–E). In contrast, in the models with low *RARA* mRNA expression, no blast reduction in the bone marrow and spleen or prolongation of survival was observed (Supplementary Fig. S9F–I). This suggests that elevated levels of *RARA* mRNA could be used as a correlated surrogate measurement for the *RARA* SE to detect cancer cells predisposed to respond to SY-1425 *in vivo*.

### **ATRA fails to show efficacy in *RARA*-high models**

The less potent and less selective *RAR* agonist ATRA, used clinically for treating APL, has had limited success in non-APL AML (35,36). Indeed, ATRA was found to be less effective than SY-1425 in reducing proliferation of AML cell lines (Supplementary Fig. S10A). To explore whether the increased potency, selectivity, and significantly improved



pharmacokinetics of SY-1425 vs. ATRA are relevant *in vivo*, we compared the effect of SY-1425 to ATRA in the *RARA* mRNA high PDX model AM5512. SY-1425 and ATRA were dosed twice daily with doses calculated to achieve exposure levels in mice similar to the human exposure observed in the clinic (33,34,37,38) (Supplementary Fig. S8A–B). SY-1425 greatly reduced tumor burden in the peripheral blood to <5% blasts, while ATRA treatment provided only a slight reduction in peripheral blast count compared to vehicle (Fig. 4G). Unlike SY-1425, the tumor burden in ATRA treated animals failed to decrease by two weeks, at which point the mice were sacrificed due to weight loss and progressive disease. SY-1425 also reduced spleen and bone marrow tumor burden compared to vehicle and ATRA (Supplementary Fig. S10B–C). Finally, SY-1425, but not ATRA, prolonged survival compared to vehicle (Fig. 4H). These data are consistent with the less potent anti-proliferative effect of ATRA on *RARA*-high cell lines compared to SY-1425 (7–21 fold less potent, Supplementary Fig. S10A) and improved pharmacology of SY-1425 including longer half-life, more stable repeat dosing exposure, and reduced sequestration.

### SY-1425 induces differentiation in *RARA*-high models

To further investigate the mechanism of action of SY-1425 in the *RARA*-high model (AM5512), a study was performed in which bone marrow and blood was sampled weekly, and analyzed by H&E staining and Ki67 IHC. Peripheral blood and bone marrow were found to closely mirror each other with respect to percent tumor burden (Supplementary Fig. S10D). At day 14, when the tumor burden in vehicle and treatment arms began to diverge, we observed marked morphologic differences between treated and untreated mice in both blood and bone marrow. In SY-1425 treated mice, we observed morphologic changes consistent with promotion of myeloid differentiation including banded nuclei and increased cytoplasm to nuclear area (Fig. 5A) compared to a high degree of poorly differentiated blasts in the vehicle treated mice (Fig. 5B). In addition, Ki67, a marker of cellular proliferation, was greatly reduced in the bone marrow of SY-1425 treated mice compared to those treated with vehicle (Fig. 5A–B inset).

To further investigate the hypothesis that SY-1425 induces differentiation in *RARA*-high, but not *RARA*-low AML cells, we analyzed the response to SY-1425 in a number of cell line models in more detail. We found that upon SY-1425 treatment, known granulocytic differentiation and retinoic acid response genes (39–42) were upregulated in the *RARA*-high cell line MV4–11, but not in the *RARA*-low cell line OCI-M1. In particular, CD38, which is a marker of early myeloid maturation, was found to be strongly induced in *RARA*-high, but not *RARA*-low cell lines at the mRNA (Fig. 5C) and protein level (Fig. 5D). Other myeloid differentiation markers such as ITGAX (CD11c) (Supplementary Fig. S11A), ITGAM (CD11b) (Supplementary Fig. S11B), and CD66 (Supplementary Fig. S11C) were more strongly induced in MV4–11 (*RARA*-high) and NB-4 (APL) than OCI-M1 (*RARA*-low).

We then sought to expand these findings beyond cell lines and analyzed 5 primary AML patient samples, three of which displayed high *RARA* mRNA levels (*RARA*-high) and two of which displayed low *RARA* mRNA levels (*RARA*-low). When treated *ex vivo* with 50 nM SY-1425, a similar trend of CD38 maturation marker induction in *RARA*-high, but not *RARA*-low cells was observed (Fig. 5E). While some AML is classified as CD38 positive

on the basis of CD38 dim expression, these were gated on a high mean fluorescent intensity level which was achieved only after exposure to SY-1425. Comparing the induction in RARA-high vs. RARA-low finds a significantly greater percentage of CD38 high phenotype cells in the RARA-high patients (Supplementary Fig. S11D).

### **Transcriptional response in RARA-high cells treated with SY-1425 is similar to changes in APL cells treated with retinoids**

To investigate the similarity of SY-1425 response in RARA-high AML to retinoid response in APL, we assayed the gene expression of three RARA-high cell lines and the NB-4 APL cell line following treatment with either SY-1425 or vehicle. At a global level, the transcriptional changes observed after SY-1425 were broadly consistent between the RARA-high cell lines and NB-4, an APL cell line (Fig. 6A). We next performed gene set enrichment analysis (GSEA) to query whether the transcriptional response of RARA-high cell lines to SY-1425 resembles gene sets of chemical or genetic perturbations found in the literature. Two of the most highly associated gene sets ( $FDR < 10^{-4}$ ) were relevant to acute promyelocytic leukemia (APL) pathogenesis or response to ATRA (tretinoin) (Fig. 6B, Supplementary Table S5). We next compared the transcriptional response of RARA-high cell lines to changes previously described in APL cells treated with ATRA *ex vivo* (43). We found that the genes differentially regulated in RARA-high AML cell lines have largely consistent directionality with those in ATRA treated APL patient samples (t-test  $p < 10^{-16}$ ) (Fig. 6C). To further characterize the transcriptional response to SY-1425, we performed GSEA on pathways gene sets and found that immune cell pathways were induced and MYC target genes were down regulated ( $FDR < 0.01$ , Supplementary Fig. S12A, Supplementary Table S6) consistent with the observed growth arrest and pro-differentiation effect. We conclude that the transcriptional response of APL cells to retinoids (ATRA or SY-1425) is similar to the response of RARA-high cell lines to SY-1425, suggesting an overlap in the mechanisms of action of these two agents in these two different forms of AML.

To further study the changes in epigenetic cell states induced by SY-1425 we performed ChIP-seq for RAR $\alpha$  and H3K27ac in cell lines representing APL, RARA-high AML, and RARA-low AML. Focusing on the *TGM2* locus, a well described PML-RAR $\alpha$  target gene (39) whose expression was induced in RARA-high AML and APL (Fig. 6D), we found an increase in H3K27ac in both NB-4 and the RARA-high line OCI-AML3 (Fig. 6E). There was a RAR $\alpha$  binding site in both cell lines downstream of the promoter around which acetylation was induced (Fig. 6E). Globally, the majority of genes bound by RAR $\alpha$  in NB-4 were also bound by RAR $\alpha$  in the RARA-high cells and to a lesser degree in the RARA-low cells (Supplementary Fig. S12B). Since super-enhancer analysis has been hypothesized to reveal cell states (6,7), we also performed a clustering analysis of the differential SEs following SY-1425 treatment in all three cell types. This analysis revealed that the RARA-high cells clustered more closely with NB-4 than with the RARA-low cells (Supplementary Fig. S12C–D). To examine whether the H3K27ac peaks induced by SY-1425 regulate known sets of differentiation genes, we used the GREAT method (44), which detects enrichment of genes near genomic regions of interest. We found strong overlap between the genes near enhancers induced in the RARA-high cells and genes induced by ATRA and bound by the PML-RAR $\alpha$  fusion protein in APL cell lines (39) (Fig. 6F, Supplementary Table S7). These

results show that the response of enhancers in RARA-high AML cells to SY-1425 is similar to that associated with treatment of APL cells with ATRA.

### **SY-1425 exerts transcriptional and chromatin alterations in RARA-high cell lines**

In addition to the similarities with APL, we sought to better understand the transcriptional and epigenomic consequences of SY-1425 treatment. Therefore, the global transcriptional changes and chromatin alterations were examined to study the relationship between RAR $\alpha$  target genes, chromatin activation, and mRNA regulation. Of particular interest was whether RAR $\alpha$  required redistribution to activate genes upon treatment or showed switch-like behavior at its original positions. We observed large changes after treatment with SY-1425 in both gene expression and enhancer score in the RARA-high lines, but little to no changes in the RARA-low cell lines, suggesting that the transcriptional and epigenomic changes are due to RAR $\alpha$  cell state and correlate with cell line sensitivity to SY-1425 (Fig. 7A, Supplementary Fig. S13A–B). Further supporting the role of RAR $\alpha$  in the SY-1425 response, we found that genes and enhancers bound by RAR $\alpha$  in the vehicle condition were more likely to be induced by SY-1425 treatment (Fig. 7B–C, Supplementary Fig. S13C). To further test whether part of the mechanism of action of SY-1425 could be through redistribution of RAR $\alpha$  among potential binding sites, we investigated the difference in RAR $\alpha$  binding between SY-1425 and vehicle treatment conditions in the RARA-high AML cell lines OCI-AML3 and MV4–11. Large changes in RAR $\alpha$  binding locations with SY-1425 treatment were not observed in either RARA-high AML cell line (only 1/9691 RAR $\alpha$  peaks in OCI-AML3 and 480/14919 in MV4–11 changed). Examining the genes that were near the RAR $\alpha$  binding sites that change in MV4–11, only three genes bound by RAR $\alpha$  specifically upon treatment with SY-1425 were differentially expressed and only two genes bound by RAR $\alpha$  specifically in the vehicle condition were differentially expressed (Fig. 7D). This supports the hypothesis that RAR $\alpha$  undergoes a functional switch from repression to activation upon SY-1425 treatment rather than inducing a redistribution of RAR $\alpha$  on the chromosome.

In order to find a pharmacodynamic marker for SY-1425 treatment, we investigated the gene expression changes in RARA-high cell lines upon treatment with SY-1425. *DHRS3* showed the largest expression increase following SY-1425 treatment across RARA- high cell lines (Fig. 7A). This gene is implicated in endogenous retinoic acid metabolism and is responsive to retinoic acid levels (45–47). Furthermore, *DHRS3* had multiple RAR $\alpha$  binding sites both within and distal to the gene around which strong H3K27ac signals were observed following SY-1425 treatment (Fig. 7E). The positions of these RAR $\alpha$  binding sites were largely unchanged upon SY-1425 treatment, supporting the hypothesis that new RAR $\alpha$  binding sites are not required for the large induction of *DHRS3* expression.

## **DISCUSSION**

### **SE analysis identifies patient subsets and RAR $\alpha$ as a therapeutic target in non-APL AML**

Here we report the enhancer and transcriptional landscapes in 66 primary human AML patient samples. Using these patient-derived data sets, we identify super-enhancers that are active in AML and define the transcriptional regulatory circuits that govern this aggressive

malignancy. As a comparison, we mapped the enhancer landscapes of healthy hematopoietic stem, progenitor cells, and monocytes to provide a framework for hematopoietic differentiation states. Super-enhancer analysis allows us to map the differentiation state of primary AML blast samples into the continuum of myeloid development. Applying non-negative matrix factorization to our SE patient dataset, we identified 6 distinct patient groups that were defined by the activity of enhancers driving expression of important transcription factor genes such as *IRF8*, *PROM1*, *MEIS1*, and *HOXA/HOXB*.

To assess a potential clinical relevance of our SE-defined patient clusters we made use of the well-curated transcriptomic and clinical data provided by The Cancer Genome Atlas. We projected our patient subgroup classification onto this large cohort to understand how enhancer landscapes might correlate with patient survival. This projection analysis demonstrated divergent overall survival between individual patient clusters. We note, however, that our AML cohort was biased toward high blast count AML which correlates with *FLT3-ITD* (30) mutation and this analysis should be validated in additional patient cohorts in the future. The *FLT3-ITD*, while more frequent overall, was not correlated with the *RARA* SE.

Since we also analyzed the somatic mutation spectrum in our patient samples, we asked how mutations are distributed throughout our clusters and whether a similar clustering could have been achieved through exonic mutation analysis. While some mutations were enriched or depleted in various clusters (for example no *NPM1* mutations were found in cluster 5 or 3, and *MLL* translocations were enriched in cluster 1), other mutations such as those occurring in *TET2*, *DNMT3A*, and *RAS*, did not appear to be concentrated in a specific cluster. From this data, we conclude that clustering using SEs can provide orthogonal information that cannot be obtained by somatic mutational analysis alone.

SEs can also provide an avenue to identify novel druggable dependencies by finding those which are cancer specific or specific to certain tumor subtypes. By identifying SE associated, cluster-specific TFs we can begin to discern transcriptional regulatory circuitry. One SE-driven gene that appeared to be a key node in cluster 2 was the ligand-dependent transcription factor *RARA*. The *RARA* SE was exceptionally strong in many cluster 2 patients and *RARα* binding sites were enriched in cluster 2 SEs. The fact that this SE ranked as one of the largest enhancers in about 25% of the patient samples analyzed, while not present in normal, non-malignant CD34-positive blasts, raises the possibility that this *RARα* circuitry represents a novel tumor liability that could be pharmacologically exploited.

### **The *RARA* SE and associated high *RARA* mRNA predict response to SY-1425**

Indeed, we found that a potent and selective *RARα* agonist (SY-1425) inhibited the proliferation of cell lines that contained the *RARA* SE, but not of cell lines that did not. This correlation was also true for *RARA* mRNA levels, presumably because SEs can drive high transcriptional activity for the genes they regulate (48). We verified this unique sensitivity of *RARA*-high AML cells *in vivo* in four AML patient derived xenograft models where two *RARA*-low models showed no response to SY-1425, whereas SY-1425 treatment led to a significant reduction of tumor burden and prolongation of survival in the two *RARA*-high models. This observation does not extend to the natural retinoid ATRA, presumably due to

its lower potency, selectivity, and PK properties (37,49,50). Compared to SY-1425, ATRA has a significantly less favorable PK profile both in mice and humans due to the fact that, as a natural derivative of vitamin A, ATRA is degraded by CYP26A1 and has been reported to induce the expression of this metabolizing enzyme resulting in lower exposures upon repeat dosing (37,49). SY-1425, as a synthetic retinoid, is resistant to CYP26A1 degradation (50) and has reduced binding to other retinoic acid sequestration proteins.

### **SY-1425 exerts transcriptional and chromatin changes that lead to differentiation of RARA-high AML cells**

Investigating the molecular mechanism of SY-1425 in non-APL AML cell lines, we found that SY-1425 induced profound transcriptional changes in RARA-high, but not RARA-low cell lines (Fig 7A). When we examined the distribution of RAR $\alpha$  on chromatin and the alterations in H3K27ac before and after SY-1425 treatment, it became apparent that the chromatin location of RAR $\alpha$  was not affected by treatment with SY-1425, rather, treatment tended to induce acetylation proximal to existing RAR $\alpha$  ChIP-seq peaks. This is consistent with previously described activities of RAR $\alpha$ , including acting in a transcriptional repressive complex while in the unliganded form and in a transcriptional activator complex when bound by an agonist (51). This supports a model in which chromatin bound RAR $\alpha$  nucleates enhancer formation and gene expression in response to the ligand, SY-1425. Applying gene set enrichment analysis to the changed expression profile following SY-1425 treatment of RARA-high cells we found an induction of immune signaling pathways (integrin, protein secretion, complement, MHC pathways) and a reduction in MYC target genes. These findings are consistent with the decreased proliferation and pro-differentiation effects observed in cell lines and xenograft models following SY-1425 treatment. Specifically, we found myeloid differentiation RAR $\alpha$  target genes, like *ITGAX* (encoding CD11c), *ITGAM* (encoding CD11b), and *CD38* to be induced in RARA-high, but not RARA-low AML cell lines. Moreover, histology of the bone marrow from RARA-high PDX models treated with SY-1425 revealed morphological changes consistent with differentiation and a reduction in the proliferation marker Ki67 (Fig. 5 A and B).

### **The transcriptional response of RARA-high AML cells to SY-1425 is similar to the response of APL cells to retinoids**

Since AML blasts that either contain a *PML-RARA* fusion (APL) or an SE at the *RARA* locus seem to both have a dependency on RAR $\alpha$ , we compared the transcriptional response and epigenetic state in representative APL or RARA-high cell lines following RAR $\alpha$  agonist treatment. We found the gene expression and enhancer responses of RARA-high AML cell lines to SY-1425 to be very similar to the responses of APL cells to ATRA or SY-1425. Gene sets of APL gene expression response to either treatment or genetic perturbation matched the response of RARA-high AML to SY-1425 at the gene expression and enhancer acetylation level. Across the genome, RAR $\alpha$  binding was highly conserved between the APL cell line NB-4 and RARA-high AML cell lines and showed less similarity to the RARA-low AML cell lines. We conclude, that many aspects of the well-studied action of retinoids on APL cells (43,52–55) also apply to the treatment of RARA-high cells (defined here) with SY-1425. This includes the initial oncogenic cell state and the induction of differentiation and loss of proliferation after treatment with retinoids.

### Proposed model of SY-1425 activity in non-APL AML

These findings support a model (Fig. 7F) where, just as in APL where the PML-RARA fusion protein acts as a transcriptional repressor driving the undifferentiated state of AML blasts, SE-induced overexpression of unliganded RAR $\alpha$  acts as a transcriptional repressor of genes under the control of RAR $\alpha$ . This assumes that the *RARA* SE and cell state are linked to super-physiological levels of RAR $\alpha$  or local depletion of endogenous retinoic acid such that the balance is distorted. The SE may also favor a more repressive isoform of RAR $\alpha$  by altering the transcriptional start site of the *RARA* gene as noted with RAR $\alpha$ 2 (56). When APL cells are treated with ATRA, the PML-RARA fusion protein is degraded and the remaining wildtype RAR $\alpha$  is induced by ATRA to function as a transcriptional activator (35,57). Similarly, in the case of RARA-high AML cells, SY-1425 functions as an agonist turning RAR $\alpha$  into a transcriptional activator. RAR $\alpha$  binding to the genes and regulatory regions nucleates enhancer formation to drive upregulated expression of target genes in the presence of SY-1425. This potentially reactivates differentiation pathways and drives the cells to terminal differentiation and growth arrest. Further validation of this model could be explored in future studies to demonstrate increased repressive complex association and activity with RAR $\alpha$  in RARA-high cells. Alternatively, it could be conjectured that the RARA-high state merely potentiates the cells to gene activation without an active role in repression.

### A biomarker directed clinical trial for SY-1425 in AML and MDS

In summary, through the analysis of super-enhancers in non-APL AML patient blasts, we have discovered a novel patient subgroup that is characterized by an SE at the *RARA* locus, predisposing cells to exquisite sensitivity to a potent and selective RAR $\alpha$  agonist, SY-1425. SY-1425 acts through the induction of differentiation and arrest of proliferation in these cells employing a mechanism of action similar to that of retinoids in APL. While the discovery of this new cancer vulnerability was made possible by genome wide SE analysis, there are multiple transcriptional readouts associated with the *RARA* SE that now can be used clinically to identify this patient population.

Previous clinical studies of retinoids in non-APL AML employed a variety of patient selection methods, patient background types, and chemotherapy combinations (58–60). Individual response in these trials and case reports are consistent with the possibility of a therapeutic benefit of retinoids in a subset of AML and MDS patients distinct from APL. However, prior attempts may have suffered from the lack of an effective patient selection strategy. In the case of ATRA it is also possible that insufficient potency, non-selectivity over other RAR subtypes (in addition to other nuclear hormone receptors and sequestration proteins), short half-life, and diminished exposure after repeat dosing may have contributed to limited responses. Moreover, the increased reduction in blast count and survival seen with SY-1425 versus ATRA in our models is consistent with the results from clinical studies demonstrating increased CR rates of tamibarotene over ATRA in APL (33,38,61). The preclinical data presented here has led to the development of a clinical patient selection strategy utilizing an *RARA* SE based biomarker for patient selection in a Phase 2 study of SY-1425 in non-APL AML and MDS patients (NCT02807558).



## METHODS

### Sample collection and processing

Normal donor human blood cells were obtained fresh from AllCells (Alameda, CA) and FACS-enriched. Human AML samples were obtained from patients at the Stanford Medical Center with informed consent, according to Institutional Review Board (IRB)-approved protocols (Stanford IRB no 18329 and 6453). Mononuclear cells were isolated from each AML sample via Ficoll separation (GE Healthcare Life Sciences, Pittsburg, PA) and cryopreserved in liquid nitrogen in 90% FBS + 10% DMSO. All experiments presented here were conducted on freshly thawed cells. Criteria for inclusion of AML samples in this study were pre-established. Samples were included based on blast percentage at sample collection. For normal donors, no exclusion criteria were used. All AML samples were thawed in IMDM + 10% FBS + 200 U/ml DNase (Worthington Biochemical, Lakewood, NJ)

### MDS samples

MDS patient samples were acquired from DVbiologics and processed as described in ChIP-seq methods. MDS sample 1 was from the bone marrow of a Caucasian female age 67. MDS sample 2 was from the bone marrow of a Caucasian female age 92.

### Cell Culture

We obtained human AML cell lines OCI-AML3, Sig-M5, NOMO-1, and OCI-M1 from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, Brunswick, Germany) We obtained other human AML cell lines (HL-60, MV-4-11, THP-1, KG-1a, HEL and Kasumi-1) from American Tissue Culture Collection (ATCC, Manassas, Virginia). All cell lines were obtained during 2014–2015. Cell lines were incubated at 37°C under 5% CO<sub>2</sub> in RPMI 1640 plus 10% FBS and additional growth factors as necessary according to the tissue bank guidelines for each cell line. Mycoplasma testing was performed at least annually using the MycoAlert™ (Lonza) detection kit. Cell lines identity was confirmed at the time of study using the ATCC Human STR Profiling Cell Authentication Service. Cell passage number was maintained below 20 culture splits.

### Cell Viability

Preparation Cell viability/proliferation studies were assays using ATPlite (Perkin Elmer) following the manufacturer's instructions and analyzed using GraphPad Prism version 6.0. Extended description of study protocol is included in the Supplementary Methods.

### ChIP-seq

Preparation and analysis of ChIP-seq are described in full detail in Supplementary Methods. Raw data has been submitted to the SRA under accession numbers SRP103200 (primary samples) and SRP103029 (cell lines).

### RNA-seq

AML samples were homogenized in 1 mL Trizol and RNA isolated using RNeasy (Ambion®, ThermoFisher, Waltham MA, USA) according to manufacturer instructions.

RNA libraries were prepared and sequenced as described previously (5). Analysis of RNA-seq data is described in detail in Supplementary Methods. Raw data has been submitted to the SRA under accession number SRP103200.

### Expression Studies in AML cell lines

Expression studies were performed using TRIzol (Thermo Fisher Scientific) for extraction, mirVana (Thermo Fisher Scientific) purification kits for RNA isolation, and were analyzed on Affymetrix PrimeView arrays. Full details of preparation and analysis are provided in the Supplementary Methods. Raw data has been submitted to GEO under the accession GSE97331.

### In vivo studies

The PDX studies were performed at Crown Bioscience using their HuKemia™ systemic models. Raw RNA-seq data on the models was provided by Crown Bioscience and analyzed as per the RNA-seq methods above. FACS analysis was performed by Crown Biosciences. The study protocols and procedures involving the care and use of animals were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Crownbio prior to conduct. During the studies, the care and use of animals was conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Slides for H&E and Ki67 were made from FFPE blocks from Crown Biosciences that were prepped and stained at the Specialized Histopathology Services – Longwood (DF/HCC, Brigham and Womens). Additional methods for *in vivo* studies provided in supplementary methods.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgments

Thank you to Dr. Jason Marineau and Dr. Kevin Sprott for help on chemistry review and sourcing and Dr. Eric Olson for guidance. Thank you to Dr. Abner Louissaint for advice and interpretation of histopathology.

#### Grant Support

Supported by Stinehart-Reed Foundation (R.M.), Ludwig Center for Cancer Stem Cell Research (R.M.), NIH (R01CA18805 to R.M.). R.M. is a New York Stem Cell Foundation Robertson Investigator and Leukemia and Lymphoma Society Scholar.

### References

1. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. *The Lancet*. 2013; 381:484–495.
2. Surveillance, Epidemiology, and End Results (SEER) Program Populations. National Cancer Institute, DCCPS, Surveillance Research Program; 1969–2015. ([www.seer.cancer.gov/popdata](http://www.seer.cancer.gov/popdata))released December 2016
3. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer Genome Landscapes. *Science*. 2013; 339:1546–58. [PubMed: 23539594]
4. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, et al. Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma. *Cancer Cell*. 2013; 24:777–790. [PubMed: 24332044]

5. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers. *Cell*. 2013; 153:320–34. [PubMed: 23582323]
6. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, et al. Super-Enhancers in the Control of Cell Identity and Disease. *Cell*. 2013; 155:934–47. [PubMed: 24119843]
7. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. *Cell*. 2013; 153:307–19. [PubMed: 23582322]
8. Hnisz D, Schuijers J, Lin CY, Weintraub AS, Abraham BJ, Lee TI, et al. Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers. *Mol Cell*. 2015; 58:362–70. [PubMed: 25801169]
9. Vahedi G, Kanno Y, Furumoto Y, Jiang K, Parker SCJ, Erdos MR, et al. Super-enhancers delineate disease-associated regulatory nodes in T cells. *Nature*. 2015; 520:558–62. [PubMed: 25686607]
10. Koues OI, Kowalewski RA, Chang L-W, Pyfrom SC, Schmidt JA, Luo H, et al. Enhancer Sequence Variants and Transcription-Factor Deregulation Synergize to Construct Pathogenic Regulatory Circuits in B-Cell Lymphoma. *Immunity*. 2015; 42:186–98. [PubMed: 25607463]
11. Adam RC, Yang H, Rockowitz S, Larsen SB, Nikolova M, Oristian DS, et al. Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice. *Nature*. 2015; 521:366–70. [PubMed: 25799994]
12. Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, Spann NJ, et al. Environment Drives Selection and Function of Enhancers Controlling Tissue-Specific Macrophage Identities. *Cell*. 2014; 159:1327–40. [PubMed: 25480297]
13. Liu C-F, Lefebvre V. The transcription factors SOX9 and SOX5/SOX6 cooperate genome-wide through super-enhancers to drive chondrogenesis. *Nucleic Acids Res*. 2015; 43:8183–203. [PubMed: 26150426]
14. Delescluse C, Cavey MT, Martin B, Bernard BA, Reichert U, Maignan J, et al. Selective high affinity retinoic acid receptor alpha or beta-gamma ligands. *Mol Pharmacol*. 1991; 40:556–562. [PubMed: 1656191]
15. Miwako I, Kagechika H. Tamibarotene. *Drugs Today*. 2007; 43:563. [PubMed: 17925887]
16. Beard RL, Duong TT, Teng M, Klein ES, Standevan AM, Chandraratna RA. Synthesis and biological activity of retinoic acid receptor- $\alpha$  specific amides. *Bioorg Med Chem Lett*. 2002; 12:3145–3148. [PubMed: 12372520]
17. Umemiya H, Fukasawa H, Ebisawa M, Eyrolles L, Kawachi E, Eisenmann G, et al. Regulation of retinoid actions by diazepinylbenzoic acids. 1 retinoid synergists which activate the RXR-RAR heterodimers. *J Med Chem*. 1997; 40:4222–4234. [PubMed: 9435893]
18. Gehin M, Vivat V, Wurtz J-M, Losson R, Chambon P, Moras D, et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. *Chem Biol*. 1999; 6:519–29. [PubMed: 10421757]
19. Whyte, Wa, Orlando, Da, Hnisz, D., Abraham, BJ., Lin, CY., Kagey, MH., et al. *Cell*. Vol. 153. Elsevier Inc; 2013. Master transcription factors and mediator establish super-enhancers at key cell identity genes; p. 307-19.
20. Javierre BM, Burren OS, Wilder SP, Kreuzhuber R, Hill SM, Sewitz S, et al. Lineage-Specific Genome Architecture Links Enhancers and Non-coding Disease Variants to Target Gene Promoters. *Cell*. 2016; 167:1369–1384. e19. [PubMed: 27863249]
21. Corces MR, Buenrostro JD, Wu B, Greenside PG, Chan SM, Koenig JL, et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. *Nat Genet*. 2016; 48:1193–203. [PubMed: 27526324]
22. Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. *Blood*. 2016; 127:42–52. [PubMed: 26660432]
23. Pastore F, Levine RL. Epigenetic regulators and their impact on therapy in acute myeloid leukemia. *Haematologica*. 2016; 101:269–78. [PubMed: 26928248]
24. Garcia-Cuellar M-P, Steger J, Fuller E, Hetzner K, Slany RK. Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia. *Haematologica*. 2015; 100:905–13. [PubMed: 25911551]


25. Huang Y, Sitwala K, Bronstein J, Sanders D, Dandekar M, Collins C, et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. *Blood*. 2012; 119:388–98. [PubMed: 22072553]
26. TCGA Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*. 2013; 368:2059–74. [PubMed: 23634996]
27. Yokoyama A. Transcriptional activation by MLL fusion proteins in leukemogenesis. *Exp Hematol*. 2017; 46:21–30. [PubMed: 27865805]
28. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining Roles for HOX and MEIS1 Genes in Induction of Acute Myeloid Leukemia. *Mol Cell Biol*. 2001; 21:224–34. [PubMed: 11113197]
29. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study. *J Clin Oncol*. 2005; 23:9234–42. [PubMed: 16275934]
30. Levis M, Small D. FLT3: ITDoes matter in leukemia. *Leukemia*. 2003; 17:1738–52. [PubMed: 12970773]
31. Zhou G-B, Zhang J, Wang Z-Y, Chen S-J, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. *Philos Trans R Soc B Biol Sci*. 2007; 362:959–71.
32. Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MGD, Jädersten M, et al. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. *Nat Commun*. 2015; 6:5901. [PubMed: 25574665]
33. Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, Hiraoka A, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. *Blood*. 1997; 90:967–973. [PubMed: 9242525]
34. Kanai F, Obi S, Fujiyama S, Shiina S, Tamai H, Mochizuki H, et al. An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma. *Hepatol Int*. 2014; 8:94–103. [PubMed: 26202410]
35. Johnson DE, Redner RL. An ATRActive future for differentiation therapy in AML. *Blood Rev*. 2015; 29:263–8. [PubMed: 25631637]
36. Brown G, Hughes P. Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia. *Leuk Res Treat*. 2012; 2012:1–11.
37. Muindi J, Frankel S, Miller WJ, Jakubowski A, Scheinberg DA, Young C, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia [published erratum appears in *Blood* 1992 Aug 1; 80 (3): 855]. *Blood*. 1992; 79:299–303. [PubMed: 1309668]
38. Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J, et al. Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial. *J Clin Oncol*. 2014; 32:3729–35. [PubMed: 25245439]
39. Martens JHA, Brinkman AB, Simmer F, Francoijs K-J, Nebbioso A, Ferrara F, et al. PML-RAR $\alpha$ /RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. *Cancer Cell*. 2010; 17:173–85. [PubMed: 20159609]
40. Mar JC, Quackenbush J. Decomposition of gene expression state space trajectories. *PLoS Comput Biol*. 2009; 5:e1000626. [PubMed: 20041215]
41. Nasr R, Guillemin M-C, Ferhi O, Soilihi H, Peres L, Berthier C, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. *Nat Med*. 2008; 14:1333–42. [PubMed: 19029980]
42. Jiao X, Hooper SD, Djureinovic T, Larsson C, Wärnberg F, Tellgren-Roth C, et al. Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing. *BMC Genomics*. 2013; 14:165. [PubMed: 23496902]
43. Meani N, Minardi S, Licciulli S, Gelmetti V, Coco FL, Nervi C, et al. Molecular signature of retinoic acid treatment in acute promyelocytic leukemia. *Oncogene*. 2005; 24:3358–68. [PubMed: 15735696]

44. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT improves functional interpretation of cis-regulatory regions. *Nat Biotechnol.* 2010; 28:495–501. [PubMed: 20436461]
45. Adams MK, Belyaeva OV, Wu L, Kedishvili NY. The Retinaldehyde Reductase Activity of DHRS3 Is Reciprocally Activated by Retinol Dehydrogenase 10 to Control Retinoid Homeostasis. *J Biol Chem.* 2014; 289:14868–80. [PubMed: 24733397]
46. Billings SE, Pierzchalski K, Butler Tjaden NE, Pang X-Y, Trainor PA, Kane MA, et al. The retinaldehyde reductase DHRS3 is essential for preventing the formation of excess retinoic acid during embryonic development. *FASEB J.* 2013; 27:4877–89. [PubMed: 24005908]
47. Zolfaghari R, Chen Q, Ross AC. DHRS3, a retinal reductase, is differentially regulated by retinoic acid and lipopolysaccharide-induced inflammation in THP-1 cells and rat liver. *AJP Gastrointest Liver Physiol.* 2012; 303:G578–88.
48. Niederriter A, Varshney A, Parker S, Martin D. Super Enhancers in Cancers, Complex Disease, and Developmental Disorders. *Genes.* 2015; 6:1183–200. [PubMed: 26569311]
49. Topletz AR, Tripathy S, Foti RS, Shimshoni JA, Nelson WL, Isoherranen N. Induction of CYP26A1 by Metabolites of Retinoic Acid: Evidence That CYP26A1 Is an Important Enzyme in the Elimination of Active Retinoids. *Mol Pharmacol.* 2015; 87:430–41. [PubMed: 25492813]
50. Osanai M. Expression of the Retinoic Acid-Metabolizing Enzyme CYP26A1 Limits Programmed Cell Death. *Mol Pharmacol.* 2005; 67:1808–17. [PubMed: 15703382]
51. Niederreither K, Dollé P. Retinoic acid in development: towards an integrated view. *Nat Rev Genet.* 2008; 9:541–53. [PubMed: 18542081]
52. Liu M-J, Wang Z, Wu R-C, Sun S-Q, Wu Q-Y. Monitoring all-trans-retinoic acid-induced differentiation of human acute promyelocytic leukemia NB4 cells by Fourier-transform infrared spectroscopy. *Leukemia.* 2003; 17:1670–4. [PubMed: 12886260]
53. Yang L, Zhao H, Li S-W, Ahrens K, Collins C, Eckenrode S, et al. Gene expression profiling during all-trans retinoic acid-induced cell differentiation of acute promyelocytic leukemia cells. *J Mol Diagn.* 2003; 5:212–221. [PubMed: 14573779]
54. Kamashev D. PML-RARA-RXR Oligomers Mediate Retinoid and Rexinoid/cAMP Cross-Talk in Acute Promyelocytic Leukemia Cell Differentiation. *J Exp Med.* 2004; 199:1163–74. [PubMed: 15096541]
55. Idres N, Benoit G, Flexor MA, Lanotte M, Chabot GG. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites. *Cancer Res.* 2001; 61:700–705. [PubMed: 11212271]
56. Gianni M, Maddalena F, Marco B, Mami K, Adriana Z, Gabriela P, et al. RAR $\alpha$ 2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells. *Oncotarget.* 2016; 8:37041–60.
57. Licht JD. Reconstructing a disease: What essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia? *Cancer Cell.* 2006; 9:73–74. [PubMed: 16473273]
58. Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic leukemia: where did we start, where are we now, and the future. *Blood Cancer J.* 2015; 5:e304. [PubMed: 25885425]
59. Schenk T, Stengel S, Zelent A. Unlocking the potential of retinoic acid in anticancer therapy. *Br J Cancer.* 2014; 111:2039–45. [PubMed: 25412233]
60. Garattini E, Bolis M, Garattini SK, Fratelli M, Centritto F, Paroni G, et al. Retinoids and breast cancer: From basic studies to the clinic and back again. *Cancer Treat Rev.* 2014; 40:739–49. [PubMed: 24480385]
61. Wang J, Mi Y, Jiang B, Chen X, Ji C, Li Y, et al. Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL). *Blood.* 2015; 126:220.

### Significance

We use the super-enhancer landscape of primary human AML to elucidate transcriptional circuitry and identify novel cancer vulnerabilities. A subset of patients were found to have an SE at *RARA* which is predictive for response to SY-1425, a potent and selective *RAR $\alpha$*  agonist, in preclinical models, forming the rationale for its clinical investigation in biomarker-selected patients.



**Figure 1.**

Identification, refinement, and clustering of cancer-specific super-enhancers in human AML.

**A**, Schematic of the high-throughput chromatin immunoprecipitation pipeline used to generate super-enhancer maps in human AML and normal blood cells. **B**, Metapeak representation of typical (TE - blue) and super (SE - red) enhancers in a single AML patient (SU223). H3K27ac ChIP-seq read density was calculated in each of 40 bins across each enhancer type (either typical or super) and plotted as the median enhancer width (21.7 kb), in addition to 40 bins in the 3kb upstream and 40 bins in the 3kb downstream of the enhancer. Reads in each bin were normalized by the total reads in the experiment (in millions) and to the size of the bin in base pairs. The average normalized read density in each bin across all SEs or TEs was plotted, and the x-axis was normalized by the relative median widths of SEs or TEs. **C**, Quantification of the SE linked to *CDK6* for AML (top, gray), HSPC (middle, light blue), and monocyte (bottom, purple) samples. Ties are due to quantile normalization as *CDK6* often has one of the top 4 strongest super-enhancers genome-wide. **D**, The twenty most HSPC-associated and the twenty most monocyte-associated SEs were used to estimate an HSPC signature through non-negative least squares. Primary AML samples are ordered by this estimated HSPC signature (top, green bar). The heatmap depicts SE scores for the HSPC-associated and monocyte-associated SEs used in the classification. **E**, Independent components analysis of SE data from AML, HSPCs, and monocytes. **F**, Heatmap shows the NMF consensus clustering distance (fraction of NMF iterations in which a pair of samples were grouped in the same cluster; blue - low, red - high) between each sample in this study. HSPCs (light blue) and monocytes (purple) are projected

into the clustering without being allowed to contribute to the NMF. **G**, The estimated HSPC signature score (y axis) for each SE-based cluster is shown (\*\*\*)  $p < 3 \times 10^{-8}$ ).


Author Manuscript

Author Manuscript

Author Manuscript


Author Manuscript





**Figure 3.**

A subset of AML patients have a super enhancer at the *RARA* locus. **A**, Mutual information network of the SE score between cluster-specific SEs. SEs that are linked to TFs are named and displayed in boxes, with edges to the SEs with which they have high mutual information. Each box is colored by its contribution to each cluster, with multiple clusters indicated by color stripes. TFs with motifs that are enriched in SEs specific to the clusters indicated here over active background regions are outlined in red. Non-TF-linked SEs are indicated as gray circles. **B**, Boxplot showing the score of the *RARA* SE (y-axis) and corresponding cluster median (black bar), grouped by cluster membership (x-axis). **C**, H3K27ac ChIP-seq tracks at chr17:38,464,514–38,515,430 with large SEs shown in red and non-SE tracks shown in gray. **D**, Rank ordering of enhancers in a single patient sample (SU204). The SE linked to the *RARA* locus is indicated and is the third largest enhancer in this sample. **E**, Distribution of enhancer scores for the *RARA* enhancer across the 66 non-APL AML patient cohort. Crimson indicates samples where the *RARA* SE is amongst the top 20 largest enhancers in the sample; red indicates the same for the top 100 enhancers; gray is for remaining samples. The asterisks indicate the samples shown in the plot in (C). **F**, *RARA* mRNA levels (assessed by RNA-seq) in patient samples with differential *RARA* enhancer score. The top 25% of samples by enhancer score contain significantly higher *RARA* mRNA levels ( $p < 0.0001$ , two tail T-test with Welch's correction).

**Figure 4.**

The presence of a *RARA* SE correlates with sensitivity to SY-1425 in non-APL AML cell lines and PDX models. **A**, H3K27ac tracks at the *RARA* locus for RARA-low cell lines in blue (HEL, KG1a) and RARA-high in red (MV411, AML3, EOL1, SigM5). Blue highlighted region indicates the *RARA* SE. **B**, Anti-proliferative response of non-APL AML cell lines to SY-1425 as assessed by ATPlite (PerkinElmer) for 2 RARA-low (blue) and 4 high (red). **C**, Effect of SY-1425 in AM5512 non-APL RARA-high PDX model. Tumor growth was monitored by measuring human CD45 positive cells in mouse circulation with treatment initiated 30 days after inoculation. **D**, Effect on percent human CD45 positive in peripheral blood of SY-1425 in AM8096 non-APL RARA-high PDX model. Treatment was initiated 43 days after inoculation. **E**, AM7577 non-APL RARA-low PDX model showing days post treatment initiation versus percent positive cells for human CD45. Treatment was initiated 36 days after inoculation. **F**, AM7440 non-APL RARA-low PDX model showing days post treatment initiation versus percent positive cells for human CD45. Treatment was initiated 105 days after inoculation. **G**, Comparison of ATRA (blue) with SY-1425 (red) and vehicle (black) in AM5512 non-APL RARA-high PDX model. Treatment was started 23 days after inoculation Mice were treated with 3mg/kg BID for SY-1425 or 4mg/kg BID for

ATRA. **H**, Survival plot for study in (G) SY-1425 treated (red), ATRA (blue), or Vehicle (black). SY-1425 shows significant prolongation of survival (0.02 Mantel-Cox test).


Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript



**Figure 5.**

SY-1425 induces maturation in RARA-high AML. **A–B**, Histology from bone marrow for (A) SY-1425 treated and (B) Vehicle treated. H&E staining of bone marrow from mice at day 14 of treatment shown at 100x. Inset on each image is Ki67 staining from the same bone marrow and time at 40x. **C**, *CD38* mRNA expression analyzed by microarray in an APL cell line (NB4 – blue), a RARA-high cell line (MV-411 – red), and a RARA-low cell line (OCI-M1 – gray). Error bars represent standard deviation of three biological replicates. **D**, CD38 protein expression analyzed by flow cytometry in an APL cell line (NB4 – blue), a RARA-high cell line (MV-411 – red), and a RARA-low cell line (OCI-M1 – gray). Error bars represent standard deviation of three biological replicates. **E**, Plot of CD38 high induction for three RARA-high AML patients (left, red) and two RARA-low (right, blue) at indicated time points. Samples were mononuclear cells from AML patients tested for *ex vivo* response to 50nM SY-1425.

**Figure 6.**

SY-1425 shows similar response in RARA-high AML cell lines to APL. **A**, Gene expression response to SY-1425 (log<sub>2</sub> fold-change) by Affymetrix probes in the APL cell line NB-4 and the RARA-high cell lines OCI-AML3 and MV4-11. Probes with FDR<0.01 in joint group of OCI-AML3 and MV4-11 (n=575) are shown. Probes are sorted by log<sub>2</sub> fold-change in joint group of OCI-AML3 and MV4-11. **B**, Gene sets from the perturbation gene sets (MSigDB C2.CGP) that are enriched by GSEA in SY-1425 response in the RARA-high cell lines (top 5 gene sets by FDR, all of which are FDR<0.01). Gene sets referencing Tretinoin (ATRA) or APL are indicated in blue. X-axis indicates normalized enrichment score (NES). **C**, Log<sub>2</sub> fold change of genes in RARA-high AML cell lines (OCI-AML3 and MV4-11) upon SY-1425. The 69 genes differentially expressed in both the RARA-high AML cell lines upon SY-1425 and the *ex-vivo* APL patient samples upon retinoic acid treatment (Meani et al. 2005) are shown. Colors indicate the direction of change in the APL patient samples. **D**, Gene expression fold induction of TGM2 by SY-1425 (AML cell lines) or SY-1425 and ATRA (NB-4). Gray bars indicate RARA-low lines, red bars indicate RARA-high lines, and blue bars indicate the APL cell line. **E**, H3K27ac and RARα ChIP-seq signal at the *TGM2* locus (chr20:36,749,636–36,841,254) in OCI-AML3 (RARA-high AML) and NB-4 (APL). Arrows indicate RARα binding site. **F**, GREAT analysis of gene sets enriched in H3K27ac


peaks that are up-regulated by SY-1425 in the RARA-high cell lines (OCI-AML3 and MV4-11). Top 5 (by FDR) perturbation gene sets are shown (full data in Supplementary Table S7).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 7.** SY-1425 induces transcriptional and epigenetic alterations. **A**, Volcano plots of gene expression response to SY-1425 by Affymetrix probes in RARA-high cell lines (OCI-AML3, MV4-11, and Sig-M5) and RARA-low cell lines (OCI-M1, KG-1a, Kasumi-1). Red points are probes that map to *DHRS3*. **B**, Percentage of genes in each set that are up-regulated by SY-1425 (FDR<0.05 and log<sub>2</sub> fold change >1) in each cell line. RAR $\alpha$  bound genes contain a RAR $\alpha$  ChIP-seq peak (top 4000 peaks per cell line) within the gene regulatory region of the gene (promoter+10kb up to neighboring gene's promoter). Background genes are drawn from genes with similar expression level to RAR $\alpha$  bound genes. Error bars are from bootstrapping. Numbers in the RAR $\alpha$  bound bars indicate the number of genes up-regulated and bound by RAR $\alpha$  in that cell line. **C**, Meta-peak of H3K27ac peaks in the RARA-high cell lines by the difference in H3K27ac ChIP-seq reads per million in the SY-1425 and vehicle conditions (positive values indicate more signal in SY-1425 condition). **D**, Number of genes bound by RAR $\alpha$  only in SY-1425 or vehicle conditions in MV4-11 cell line by whether their expression is differential between conditions. **E**, H3K27ac (blue: vehicle, red: SY-1425 50nM) and RAR $\alpha$  (black) ChIP-seq signal at the *DHRS3* locus (chr1:12,575,438–12,701,209) in RARA-high cell lines (OCI-AML3 and MV4-11). **F**, Proposed model of SY-1425 action in RARA-high AML. Normal

CD34+ immature myeloid cell track at the *RARA* locus shows low acetylation leading to a balance of endogenous retinoic acid (RA) and RAR $\alpha$  protein preceding normal development of granulocytes (top). Cancer cells with the SE at the *RARA* locus drive an excess RAR $\alpha$  protein causing an imbalance of protein and ligand that favors the repressive form of RAR $\alpha$  holding back maturation and enabling proliferation (middle). Treatment with SY-1425 strongly agonizes RAR $\alpha$  to re-activate myeloid signaling and cause terminal differentiation of AML cells (bottom).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript